Entrepreneur Adam Ezra Levin on the quiet cost of socially accepted marijuana use — and why high performers don’t talk about it

By Adam Ezra Levin

I didn’t look like someone with a drug problem.

I was structuring acquisitions. Raising capital. Negotiating complex transactions. Taking companies public. Managing employees across multiple states. Sitting in boardrooms with investors who trusted my judgment.

And most nights, I got high.

Not recklessly. Not in a way that alarmed anyone around me. Cannabis was increasingly legal. Socially acceptable. In many entrepreneurial circles, it wasn’t even controversial. It was treated like a healthier alternative to alcohol — a way to take the edge off after long days of pressure.

That normalization is what made it dangerous.

Because the problem with socially accepted substances is not that they destroy your life overnight. It’s that they can quietly reduce the quality of it — and you won’t always notice until much later.

In business culture, we judge impairment by one metric: Are you still producing?

Still closing deals? You’re fine.
Still raising money? You’re fine.
Still showing up to meetings and hitting targets? You’re fine.

I told myself that story for years.

Cannabis didn’t prevent me from functioning. It didn’t stop me from leading companies or executing transactions. On the surface, I was performing at a high level.

But high performance is not the same as peak clarity.

Leadership at scale requires sharp instincts. It requires the ability to sit with discomfort long enough to make the hardest call in the room. It requires urgency when others hesitate and discipline when emotions run hot.

Cannabis didn’t erase those abilities.

It softened them.

Not dramatically. Incrementally.

And in business, incremental erosion compounds.

A delayed decision. A dulled instinct. A slightly misread counterparty. A negotiation that feels “close enough.” Over years, those marginal compromises accumulate into outcomes you can’t fully explain.

The most dangerous professional impairments are the ones that allow you to keep winning — until you don’t.

Federal cannabis reform continues to gain momentum, and many policymakers — including leaders within the Trump administration — have supported modernizing outdated marijuana laws. Reform has addressed inequities and opened economic opportunities that are real and meaningful.

I support rational reform.

But legalization should not lead to denial.

Alcohol is legal and deeply embedded in corporate culture. No serious executive would argue that alcohol misuse doesn’t impair judgment, damage relationships, and destroy companies. Entire leadership collapses have been tied to alcohol abuse.

Cannabis deserves the same honest framework.

It is entirely possible to support legalization while acknowledging dependency risk. Those positions are not contradictory.

What concerns me is the cultural messaging that has shifted from “this should not be criminalized” to “this is harmless.”

Those are two very different claims.

For years, I convinced myself that if cannabis were truly a problem, I wouldn’t be succeeding.

I wouldn’t be building companies.
I wouldn’t be structuring complex transactions.
I wouldn’t be trusted with other people’s capital.

But high achievement can coexist with dependency.

In fact, in high-pressure industries, dependency often hides behind productivity. Stress becomes justification. Long days become permission. Performance becomes denial.

The truth is harder: peak performance requires clarity. And clarity is fragile.

Looking back, I don’t blame cannabis for every failure in my career. Leadership mistakes were mine. Strategic errors were mine. Ego was mine.

But I can no longer ignore that chronic use altered my judgment — not dramatically, but incrementally.

And in business, incremental impairment compounds.

Cannabis can feel like relief.

It quiets anxiety.
It softens pressure.
It creates distance from stress.

But the same mechanism that softens stress can soften edge.

Entrepreneurs are paid for edge — for conviction under uncertainty, for decision-making under fire, for seeing risk clearly while others hesitate.

When that edge dulls, even slightly, the cost may not show up immediately.

It shows up later.

In missed signals.
In strained relationships.
In decisions that felt defensible in the moment but costly in hindsight.

As cannabis becomes federally normalized, founders, executives, and investors need to speak honestly about overuse — especially in high-stakes industries where judgment is capital.

This is not a moral argument.

It is a performance argument.

If you are responsible for employees, investors, and shareholders, your cognitive clarity is not just personal — it is fiduciary.

My name is Adam Ezra Levin. I am an entrepreneur and investor who has built and operated companies across hospitality, consumer, and financial markets. My career has included taking companies public, acquiring distressed businesses, scaling brands, and navigating public setbacks.

I have seen both sides of success.

Today, I am committed to clarity, discipline, and rebuilding with sharper awareness.

Cannabis may be socially acceptable. It may soon be federally normalized.

But every entrepreneur must ask themselves an honest question:

Are you operating at your full potential — or at a chemically negotiated version of it?

In business, the difference matters.